Clinical trial
Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion (NAPA-3)
NCT00338585 is registered in ClinicalTrials.gov with ARCA Biopharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion (NAPA-3)
- Lead sponsor
- ARCA Biopharma, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- April 30, 2006
- Completion date
- March 31, 2007
- Enrollment
- 300
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.